Does the media favor XENE or EXEL?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Exelixis. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 14 mentions for Exelixis. Exelixis' average media sentiment score of 0.54 beat Xenon Pharmaceuticals' score of 0.46 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Exelixis 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or ASND?

In the previous week, Xenon Pharmaceuticals had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. Xenon Pharmaceuticals' average media sentiment score of 0.46 beat Ascendis Pharma A/S's score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SMMT or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media prefer SMMT or XENE?

In the previous week, Xenon Pharmaceuticals had 13 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 2 mentions for Summit Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.46 beat Summit Therapeutics' score of 0.36 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer BBIO or XENE?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 13 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.46 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer HALO or XENE?

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 15 mentions for Xenon Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.64 beat Xenon Pharmaceuticals' score of 0.46 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Xenon Pharmaceuticals (XENE) Competitors

$36.44 +0.28 (+0.77%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$36.48 +0.04 (+0.11%)

As of 10/9/2026 07:30 PM Eastern

Compare

XENE vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy Xenon Pharmaceuticals stock or one of its competitors? Xenon Pharmaceuticals's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Xenon Pharmaceuticals compare to Exelixis?

Xenon Pharmaceuticals (NASDAQ:XENE) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Xenon Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Exelixis. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 14 mentions for Exelixis. Exelixis' average media sentiment score of 0.54 beat Xenon Pharmaceuticals' score of 0.46 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Exelixis	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	469.69	-$345.91M	-$4.74	N/A
Exelixis	$2.32B	6.39	$782.57M	$3.18	18.82

Xenon Pharmaceuticals currently has a consensus price target of $70.14, indicating a potential upside of 92.49%. Exelixis has a consensus price target of $50.79, indicating a potential downside of 15.16%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Exelixis has a net margin of 35.33% compared to Xenon Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Exelixis	35.33%	42.17%	31.76%

Summary

Xenon Pharmaceuticals and Exelixis tied by winning 8 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	469.69	-$345.91M	-$4.74	N/A
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78

In the previous week, Xenon Pharmaceuticals had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. Xenon Pharmaceuticals' average media sentiment score of 0.46 beat Ascendis Pharma A/S's score of 0.33 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenon Pharmaceuticals currently has a consensus price target of $70.14, suggesting a potential upside of 92.49%. Ascendis Pharma A/S has a consensus price target of $313.21, suggesting a potential upside of 36.64%. Given Xenon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 70.99% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Summit Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Xenon Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Xenon Pharmaceuticals	$7.50M	469.69	-$345.91M	-$4.74	N/A

Summit Therapeutics presently has a consensus price target of $28.61, indicating a potential upside of 62.64%. Xenon Pharmaceuticals has a consensus price target of $70.14, indicating a potential upside of 92.49%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Xenon Pharmaceuticals' return on equity of -43.98% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

In the previous week, Xenon Pharmaceuticals had 13 more articles in the media than Summit Therapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 2 mentions for Summit Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.46 beat Summit Therapeutics' score of 0.36 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Xenon Pharmaceuticals beats Summit Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 13 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.46 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

BridgeBio Pharma currently has a consensus target price of $105.42, indicating a potential upside of 61.32%. Xenon Pharmaceuticals has a consensus target price of $70.14, indicating a potential upside of 92.49%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Xenon Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.44	-$724.93M	-$3.57	N/A
Xenon Pharmaceuticals	$7.50M	469.69	-$345.91M	-$4.74	N/A

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Halozyme Therapeutics presently has a consensus price target of $94.00, indicating a potential downside of 14.87%. Xenon Pharmaceuticals has a consensus price target of $70.14, indicating a potential upside of 92.49%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 15 mentions for Xenon Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.64 beat Xenon Pharmaceuticals' score of 0.46 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Xenon Pharmaceuticals' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Halozyme Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.97	$316.89M	$3.35	32.96
Xenon Pharmaceuticals	$7.50M	469.69	-$345.91M	-$4.74	N/A

Summary

Halozyme Therapeutics beats Xenon Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.50B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-7.69	13.42	274.13	26.16
Price / Sales	469.69	1,240.95	590.44	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	4.84	17.17	11.21	6.34
Net Income	-$345.91M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-4.16%	-1.33%	-0.92%	-1.41%
1 Month Performance	-38.03%	-8.44%	-4.46%	-3.48%
1 Year Performance	-8.07%	14.02%	6.94%	1.16%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	4.3972 of 5 stars	$36.44 +0.8%	$70.14 +92.5%	-11.7%	$3.50B	$7.50M	N/A	364	Analyst Forecast
EXEL Exelixis	2.6907 of 5 stars	$58.85 +0.8%	$50.29 -14.6%	+55.2%	$14.58B	$2.44B	18.51	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7883 of 5 stars	$228.03 +0.1%	$310.75 +36.3%	+6.7%	$14.21B	$814.57M	17.69	1,189
SMMT Summit Therapeutics	2.3654 of 5 stars	$17.27 +3.1%	$28.61 +65.6%	-22.3%	$13.37B	N/A	N/A	265
BBIO BridgeBio Pharma	3.9361 of 5 stars	$66.14 -1.7%	$102.61 +55.1%	+19.3%	$13.15B	$713.07M	N/A	839	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Xenon Pharmaceuticals compare to Exelixis?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Xenon Pharmaceuticals compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Xenon Pharmaceuticals compare to Exelixis?

Which has more risk & volatility, XENE or EXEL?

Do insiders & institutionals have more ownership in XENE or EXEL?

Does the media favor XENE or EXEL?

Which has preferable earnings & valuation, XENE or EXEL?

Do analysts rate XENE or EXEL?

Is XENE or EXEL more profitable?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Which has better valuation & earnings, XENE or ASND?

Does the media favor XENE or ASND?

Do analysts rate XENE or ASND?

Is XENE or ASND more profitable?

Do insiders and institutionals have more ownership in XENE or ASND?

Which has more risk and volatility, XENE or ASND?

Summary

How does Xenon Pharmaceuticals compare to Summit Therapeutics?

Which has more volatility & risk, SMMT or XENE?

Which has higher earnings and valuation, SMMT or XENE?

Do analysts rate SMMT or XENE?

Do insiders and institutionals have more ownership in SMMT or XENE?

Is SMMT or XENE more profitable?

Does the media prefer SMMT or XENE?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Does the media prefer BBIO or XENE?

Do analysts prefer BBIO or XENE?

Which has better valuation and earnings, BBIO or XENE?

Do insiders and institutionals believe in BBIO or XENE?

Is BBIO or XENE more profitable?

Which has more volatility and risk, BBIO or XENE?

Summary

How does Xenon Pharmaceuticals compare to Halozyme Therapeutics?

Do analysts recommend HALO or XENE?

Does the media prefer HALO or XENE?

Do insiders & institutionals believe in HALO or XENE?

Which has more volatility and risk, HALO or XENE?

Is HALO or XENE more profitable?

Which has better earnings and valuation, HALO or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools